Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

被引：1
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
Di Simone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett, V
Perini, Rodolfo F.
Kubiak, Peter
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Rocky Mt Canc Ctr, Denver, CO USA
[8] Arizona Oncol Associates, Tucson, AZ USA
[9] New York Oncol Hematol, Albany, NY USA
[10] Hosp Univ & Politecn La FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Kristiansand, Norway
[12] Eisai Inc, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] Eisai Ltd, Hatfield, Herts, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5008
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, Chung-Han
    Shah, Amishi Y.
    Makker, Vicky
    Taylor, Matthew
    Shaffer, David
    Hseih, James J.
    Cohn, Allen L.
    Di Simone, Chris
    Marin, Alvaro Pinto
    Rasco, Drew
    Gunnestad-Ribe, Sara
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Perini, Rodolfo
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 101 - 102
  • [2] Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, C-H.
    Shah, A. Y.
    Makker, V.
    Taylor, M. H.
    Shaffer, D.
    Hsieh, J. J.
    Cohn, A. L.
    DiSimone, C.
    Pinto Marin, A.
    Rasco, D. W.
    Ribe, S. G.
    Richards, D. A.
    Stepan, D. E.
    Dutcus, C. E.
    Wu, J.
    Schmidt, E. V.
    Perini, R. F.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 483 - +
  • [3] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Lee, C-H.
    Shah, A. Y.
    Hsieh, J. J.
    Rao, A.
    Pinto, A.
    Bilen, M. A.
    Cohn, A. L.
    Di Simone, C.
    Shaffer, D. R.
    Girones Sarrio, R.
    Ribe, S. Gunnestad
    Wu, J.
    Schmidt, E.
    Kubiak, P.
    Okpara, C. E.
    Smith, A. D.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S558 - S559
  • [4] Phase 2 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    Di Simone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett
    Kubiak, Peter
    Okpara, Chinyere
    Smith, Alan D.
    Young, Louise
    Motzer, Robert J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 133
  • [5] Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)
    McGregor, B. A.
    Lalani, A-K.
    Xie, W.
    Steinharter, J. A.
    Martini, D. J.
    Nuzzo, P. V.
    Chanza, N. Martinez
    Harshman, L. C.
    Bilen, M. A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
    Swami, U.
    Jo, Y. Jung
    Thomas, V. Mathew
    Gebrael, G.
    Li, H.
    Sayegh, N.
    Tripathi, N.
    Srivastava, A.
    Nordblad, B.
    Dal, E.
    Brundage, J.
    Campbell, P.
    Fortuna, G. Galarza
    Chehade, C. Hage
    Maughan, B. L.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1021 - S1021
  • [7] Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.
    Arance, Ana Maria
    de la Cruz-Merino, Luis
    Petrella, Teresa M.
    Jamal, Rahima
    Ny, Lars
    Carneiro, Ana
    Berrocal, Alfonso
    Marquez-Rodas, Ivan
    Spreafico, Anna
    Atkinson, Victoria
    Svedman, Fernanda Costa
    Mant, Andrew
    Smith, Alan D.
    Chen, Ke
    Diede, Scott J.
    Krepler, Clemens
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
    Arance Fernandez, A. M.
    O'Day, S. J.
    de la Cruz Merino, L.
    Petrella, T.
    Jamal, R.
    Ny, L.
    Carneiro, A.
    Berrocal, A.
    Marquez-Rodas, I.
    Spreafico, A.
    Atkinson, V. Victoria
    Svedman, F. Costa
    Smith, A. D.
    Chen, K.
    Diede, S. J.
    Krepler, C.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2020, 31 : S1173 - S1173
  • [9] Final database lock results of the phase 2 cohort of lenvatinib plus pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Rao, Arpit
    Taylor, Matthew H.
    Pinto, Alvaro
    Sarrio, Regina Girones
    Cohn, Allen Lee
    Bilen, Mehmet Asim
    Ribe, Sara Gunnestad
    Goksel, Musaberk
    Tennoe, Oyvind Krohn
    Richards, Donald
    Sweis, Randy F.
    Heinrich, Daniel
    Perini, Rodolfo
    Kubiak, Peter
    Huang, Jie
    Motzer, Robert J.
    ONCOLOGIST, 2023, 28 : S3 - +
  • [10] A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)
    Dizman, Nazli
    Adra, Nabil
    Vaishampayan, Ulka N.
    Xiao, Lianchun
    Yuan, Ying
    Campbell, Matthew T.
    Gao, Jianjun
    Zurita, Amado J.
    Jonasch, Eric
    Tannir, Nizar M.
    Shah, Amishi Yogesh
    Msaouel, Pavlos
    Hahn, Andrew Warren
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345